We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Approximately 60% to 85% of patients who develop ...

Selective interleukin-23 (IL-23) inhibitors for the management of psoriasis are administered every 8 to 12 weeks, compared with previous treatment options that required a weekly, biweekly, or monthly ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 100% of patients treated with 150 mg, 300 mg and 600 mg ...

Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin and improved the severity of disease in a phase 3 test, setting up the company to seek approval from Chinese ...

In a retrospective cohort study, treatment with an IL-23 inhibitor was associated with a similar incidence of psoriatic arthritis (PsA) as treatment with IL-2/23 inhibitors in patients with psoriasis.

The FDA expanded the indications for guselkumab (Tremfya) to include adults with moderately to severely active ulcerative colitis, Johnson & Johnson announced on Wednesday. Approval of the dual-acting ...